Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ventricular rate control in the elderly: is digoxin enough?

Rodney H Falk1

  • 1Section of Cardiology, Boston University School of Medicine, Boston, MA 02118, USA. rfalk@bu.edu

The American Journal of Geriatric Cardiology
|November 6, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Technetium Pyrophosphate Blood Pool Uptake Mistaken for Myocardial Uptake in Light-Chain Amyloidosis: A Dangerous Misinterpretation.

JACC. Case reports·2026
Same author

Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy.

Circulation. Heart failure·2026
Same author

Assessment of cardiac involvement in rare forms of amyloidosis using positron emission tomography/computed tomography with <sup>124</sup>I-evuzamitide (<sup>124</sup>I-p5+14, AT-01).

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·2026
Same author

Evaluating natural history and treatment response in cardiac amyloidosis: the evolving role of multimodality imaging.

European heart journal. Cardiovascular Imaging·2025
Same author

Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy.

JACC. Cardiovascular imaging·2025
Same author

Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis.

Blood·2025
Same journal

Systolic anterior motion of a retained anterior mitral valve leaflet following mitral valve replacement.

The American journal of geriatric cardiology·2008
Same journal

Biomarkers, age, and coronary artery remodeling in patients with acute coronary syndrome.

The American journal of geriatric cardiology·2008
Same journal

Electrocardiographic intervals in the healthy geriatric population--what are the "normals"?

The American journal of geriatric cardiology·2008
Same journal

Coronary events in persons aged 75 years or older in Finland from 1995 to 2002: the FINAMI study.

The American journal of geriatric cardiology·2008
Same journal

Sinus venosus atrial septal defect diagnosed at age 82.

The American journal of geriatric cardiology·2008
Same journal

Frailty, inflammation, and cardiovascular disease: evidence of a connection.

The American journal of geriatric cardiology·2008
See all related articles

Digoxin may not effectively control resting heart rate in atrial fibrillation patients, especially during exertion. Beta blockers and calcium channel blockers like diltiazem or verapamil are alternatives for rate control, particularly in elderly patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Untreated atrial fibrillation commonly presents with resting ventricular rates exceeding 120 beats/min.
  • Digoxin is a traditional agent for slowing ventricular response but has limitations, particularly during physical exertion.

Purpose of the Study:

  • To review the role of digoxin in managing ventricular rate in atrial fibrillation.
  • To compare digoxin's efficacy with alternative agents like beta blockers and calcium channel blockers (diltiazem, verapamil).
  • To specifically consider the implications for the elderly population.

Main Methods:

  • This is a review article, synthesizing existing literature.
  • The discussion focuses on comparative efficacy and clinical considerations of rate-controlling agents.

Related Experiment Videos

Main Results:

  • Digoxin's efficacy in rate control can be limited, especially during exertion.
  • Beta blockers and calcium channel blockers offer alternative or additive strategies for ventricular rate control.

Conclusions:

  • Alternative or add-on therapies to digoxin, such as beta blockers and calcium channel blockers, are crucial for effective rate control in atrial fibrillation.
  • Special attention should be paid to these therapeutic options in the elderly population due to potential differences in response and side effects.